#Sweden #Lund #Hansa Biopharma #IDEFIRIX #SERB Pharmaceuticals

Hansa Biopharma's Third Quarter 2026 Financial Report

Hansa Biopharma AB, listed on NASDAQ Stockholm under the ticker HNSA, has recently released its interim report detailing the financial results for the third quarter and year-to-date ending September 30, 2026. In a significant achievement, the company reported a notable increase in revenue as it moves closer to the potential U.S. launch of its leading product, Idefirix.

Strong Financial Performance

The reported revenue for the third quarter of 2026 amounted to 143.0 MSEK, a dramatic rise compared to 30.8 MSEK in the same quarter of 2025. This rise was largely fueled by the newly secured licensing agreement with SERB Pharmaceuticals, which has dramatically reshaped Hansa's financial landscape. With a total revenue of 225.7 MSEK for the nine months ending in September, up from 146.3 MSEK the previous year, Hansa is on a promising trajectory forward.

CEO Renée Aguiar-Lucander expressed confidence in the company’s current direction, citing the completion of the €115 million licensing transaction with SERB as a pivotal moment. This agreement allows SERB to exclusively market Idefirix in Europe and the Middle East/North Africa (MENA) regions, a significant step in expanding Hansa's international reach and financial foundation.

Strategic Focus and Clinical Advancements

In addition to financial gains, Hansa has initiated pivotal clinical procedures. The company celebrated the first commercial kidney transplant in Australia using Idefirix, furthering its commercial activities and reinforcing the product’s critical role in kidney transplantation for sensitized patients.

The recent changes in the board, including the election of Shannon Campbell and Gregory Perry, alongside the resignation of former board member Michael Bologna, indicate a shift towards a more dynamic leadership structure that supports Hansa's strategic initiatives.

Clinical Development and Regulatory Updates

Hansa has also made strides in clinical research, sharing results from their European post-authorization efficacy and safety study (PAES) during ASN Kidney Week, which took place on October 23. Moreover, Hansa has submitted an Investigational New Drug (IND) application to the FDA for its new therapy, HNSA-5487, aimed at treating Guillain-Barré syndrome (GBS). This highlights the company’s commitment to addressing significant unmet medical needs with innovative solutions.

Financial Summary and Outlook

A detailed glance at Hansa’s third-quarter performance reveals substantial investments in research and development despite a reported loss from operations totaling 138.6 MSEK, down from 147.6 MSEK a year prior. Operating expenses were impacted due to the increased costs associated with advancing their clinical programs and business strategies. However, cash and cash equivalents soared to 1,337.2 MSEK, a remarkable increase from 252.1 MSEK in September 2025, equipping Hansa with the necessary capital to navigate future challenges and opportunities.

In conclusion, Hansa Biopharma's third-quarter report for 2026 underscores its remarkable financial growth and strategic focus on addressing complex immune disorders through innovative treatments. As the company prepares for its potential U.S. launch of Idefirix, it exemplifies a clear momentum in advancing not just its financial health but also its commitment to transforming patient care across multiple regions.

For further details, Hansa Biopharma will host a telephone conference to discuss these updates, providing an opportunity for investors and stakeholders to engage with the leadership team directly, reinforcing transparency and a forward-looking approach in their operations.

• ---

For further insights and developments from Hansa Biopharma, stay connected via their official website.